Pilocytic astrocytoma (PA) is the most common glial cell tumor arising in children. Sporadic cases are associated with KIAA1549:BRAF fusion rearrangements, while 15-20% of children develop PA in the context of the neurofibromatosis 1 (NF1) inherited tumor predisposition syndrome. The unique predilection of these tumors to form within the optic pathway and brainstem (NF1-PA) and cerebellum (sporadic PA) raises the possibility that gliomagenesis requires more than biallelic inactivation of the NF1 tumor suppressor gene or expression of the KIAA1549:BRAF transcript. Several etiologic explanations include differential susceptibilities of preneoplastic neuroglial cell types in different brain regions to these glioma-causing genetic changes, contributions from nonneoplastic cells and signals in the tumor microenvironment, and genomic modifiers that confer glioma risk. As clinically-faithful rodent models of sporadic PA are currently under development, Nf1 genetically-engineered mouse (GEM) models have served as tractable systems to study the role of the cell of origin, deregulated intracellular signaling, non-neoplastic cells in the tumor microenvironment and genomic modifiers in gliomagenesis. In this report, we highlight advances in Nf1-GEM modeling and review new experimental evidence that supports the emerging concept that Nf1-and KIAA1549:BRAF-induced gliomas arise from specific cell types in particular brain locations.
INTRODUCTION
Tumors of the nervous system are the leading cause of cancerrelated death in children. Among the various histological subtypes, the most common brain tumor in the pediatric population is the WHO grade I pilocytic astrocytoma (PA). 1, 2 These low-grade PAs are characterized by glial fibrillary acid protein (GFAP) expression and unique histologic features, including eosinophilic granular bodies and Rosenthal fibers. 3 Unlike their more malignant counterparts, they lack palisading necrosis, high mitotic indices or pronounced nuclear atypia. However, PAs may exhibit prominent microvascular proliferation and harbor large numbers of microglia. In addition, in distinction to adult gliomas, PAs most commonly arise in the optic pathway, brainstem and cerebellum.
Until recently, the only known genetic alteration associated with PA was mutational inactivation of neurofibromatosis 1 (NF1) tumor suppressor gene in children with the NF1 inherited tumor predisposition syndrome. 4, 5 In these NF1-associated gliomas, biallelic inactivation of the NF1 gene was observed, concomitant with the loss of NF1 protein (neurofibromin) expression. 4, 6 In the context of NF1, PAs predominate in the optic pathway (optic nerve, chiasm and post-chiasmatic radiations) in children younger than 7 years of age (Figures 1a and b) . 7 While 75% of NF1-PAs are located within the optic pathway, 15-20% of these gliomas may also arise in the brainstem. 8 In contrast to NF1-associated PA, sporadic PAs usually arise in the cerebellum (Figures 1c and d ), but may also be located, with decreasing frequency, in the brainstem and optic pathway. When they form in the cerebellum, there is frequently a prominent cystic component, and surgical resection is usually curative. While NF1 loss is not found in sporadic PAs, 5, 9 converging evidence from numerous laboratories has revealed that the majority of non-NF1-associated PAs harbor a somatic rearrangement, in which the kinase domain of the BRAF gene is fused to an unknown gene (KIAA1549). This fusion event (KIAA1549:BRAF or f-BRAF) is most commonly detected in sporadic PAs arising in the cerebellum. 4, 5, 10, 11 The fact that these tumors do not progress to higher grade glial malignancies and exhibit a geographical predilection for specific midline brain regions raises the intriguing possibility that pediatric PAs are neurodevelopmental disorders. Similar to other neurodevelopmental diseases, these low-grade gliomas in children likely obey the rules that govern normal patterning in the developing central nervous system. In this review, we will discuss recent studies that collectively support a model in which pediatric gliomagenesis requires the confluence of numerous critical conditions that reflect activation of specific growth control pathways, the cell of origin, brain region-specific constraints and the local microenvironment.
GROWTH CONTROL PATHWAYS
With the identification of the NF1 gene and f-BRAF fusion event, it now becomes possible to determine how PA growth is regulated. The NF1 gene product, neurofibromin is a large cytoplasmic protein (220-250 kDa) that contains three differentially-spliced exons (9a, 23a and 48a) 12 ( Figure 2a) . While the precise function of these alternatively spliced products has not been clearly elucidated to date, they likely reflect tissue-specific or differentiation-regulated properties of neurofibromin.
RAS to its inactive GDP-bound form, thus inactivating RAS, and reducing RAS-mediated growth signaling. [18] [19] [20] In this respect, loss of neurofibromin expression results in increased RAS activity. 20, 21 Recently, array-based comparative genomic hybridization identified a low-level copy number gain of the BRAF gene in a large portion of PAs. 11, 22 Further studies demonstrated that this gain was due to a tandem duplication at 7q34 with subsequent fusion between the 5 0 end of the KIAA1549 gene and the 3 0 end of the BRAF gene (Figure 2b) . 10, 11, 22, 23 The resulting fusion transcripts contain the amino terminus of the KIAA1549 protein and the BRAF kinase domain, but lack the auto-regulatory domain of BRAF, resulting in constitutive BRAF kinase activity and downstream activation of the mitogen-activated protein kinase signaling pathway. In addition to KIAA1549:BRAF, other somatic mutations have also been reported in PA, including rare oncogenic Ras or BRAF mutations, [24] [25] [26] [27] [28] as well as SRGAP3:RAF1 26 and FAM131B:BRAF 29 gene fusions, which similarly result in increased mitogen-activated protein kinase activation.
In many cell types, RAS activation leads to increased signaling through RAS downstream effector proteins, including PI3-Kinase (PI3K)/AKT and RAF/MEK (Figure 3 ). To define how neurofibromin loss regulates glial cell proliferation downstream of RAS, a proteomic approach was utilized. Using wild-type and Nf1-deficient mouse brain astrocytes, mass spectrometry revealed increased expression of ribosomal proteins involved in protein translation following neurofibromin loss. 30 As predicted from the Neurofibromin is a 2818 amino acid protein containing three alternatively spliced exons (9a, 23a and 48a), which reflect tissue-specific or differentiation-regulated RNA splicing events. The GTPase-activating proteins-related domain of neurofibromin functions as a negative RAS regulator. (b) Schematic representation of the predicted structure of human KIAA1549:BRAF fusion proteins. Numerous distinct rearrangements have been described involving different exons from KIAA1549 and BRAF. RD, regulatory domain; KD, kinase domain. elevated ribosomal protein expression in Nf1-deficient astrocytes, these cells also exhibited increased protein synthesis resulting from hyperactivation of the mammalian target of rapamycin (mTOR) protein. mTOR is a serine/threonine kinase, which directly controls protein synthesis and ribosomal biogenesis by modulating ribosomal S6-Kinase activity. Subsequent experiments demonstrated mTOR hyperactivation in Nf1 mouse optic glioma and NF1-associated human PA tumors. In addition, a previous study showed that loss of neurofibromin expression was associated with PI3K-AKT signaling pathway activation in a single human NF1-associated PA. 6 The importance of PI3K/AKT and mTOR pathway activation to neurofibromin growth regulation in astrocytes and neural stem cells (NSCs) was further confirmed by pharmacological and genetic inhibition of mTOR function in Nf1-deficient astrocytes. 30, 31 Relevant to the treatment of NF1-PA, treatment of Nf1-deficient astrocytes with the mTOR inhibitor, rapamycin, reduced their proliferation to wild-type levels and attenuated glioma growth in a mouse model of Nf1 optic glioma. 32 In contrast, deregulated BRAF activity is thought to increase cell growth in a MEK/mitogen-activated protein kinase-dependent manner. While MEK inhibition ameliorates the growth advantage conferred by f-BRAF expression, recent studies have demonstrated that MEK activation converges on a pathway shared with NF1-PA. In cerebellar NSCs expressing f-BRAF, increased MEK activation leads to mTOR hyperactivation ( Figure 3 ). While Nf1 loss in astrocytes activates mTOR in a PI3K/AKT-dependent manner, 33 f-BRAF expression in these NSCs results in increased mTOR activation by phosphorylation and inactivation of the tuberous sclerosis complex-2 protein (tuberin), leading to elevated Rhebmediated mTOR signaling. 34 These exciting findings suggest that mTOR might be a central target for both sporadic and NF1-associated PA, and have prompted recent clinical studies using rapamycin analogs to treat these tumors.
CELL OF ORIGIN
Studies on malignant brain tumors, as well as other central nervous system tumor types (ependymoma, medulloblastoma (MB), meningioma) have demonstrated that the cell of origin and developmental stage matter greatly in the genesis of these cancers. [35] [36] [37] [38] For example, intracranial and spinal ependymomas likely arise from radial glial cells, 38 which function as NSCs in the embryo and give rise to adult NSCs. 39 Further evidence has revealed that Ink4a/Arf-/-NSCs with amplified EPHB2 from the embryonic cerebrum, but not from other regions or from adults, form ependymomas resembling human supratentorial ependymoma. 40 Similarly, distinct subgroups of MB are characterized by activation of different signaling pathways, including sonic hedgehog and WNT. 41 While the desmoplastic subtype of MB harboring mutations in the sonic hedgehog pathway likely arises from granule neuron precursors, 42 the classic subtype with aberrant WNT pathway signaling derives from mossy-fiber neuronal precursors in the dorsal brainstem. 36 The cell of origin for malignant glioma remains controversial, as these cancers can arise from numerous cell types, ranging from lateral subventricular zone (SVZ) NSCs 35, 43 and NG2 þ progenitors [44] [45] [46] [47] [48] to mature astrocytes and neurons. 49, 50 For example, conditional inactivation of Tp53, Nf1 and Pten tumor suppressor genes in mouse SVZ NSCs can induce malignant astrocytomas. 35, 43 In contrast, introducing platelet-derived growth factor into adult mouse white matter, tumor-initiating NG2 þ / GFAP À progenitor cells recruits/activates other progenitors to promote malignant glioma. 47 Similarly, other studies have suggested that more differentiated glial cell types (astrocytes) might directly transform into glioma. 49 Even more surprising is the recent report that mature neurons can undergo dedifferentiation in response to glioma-associated genetic changes to create a progenitor state sufficient to initiate glioma formation. 50 Genetically-engineered mouse (GEM) models have provided powerful instructive tools to study the cellular origins of brain tumors. While Parada and colleagues have demonstrated that malignant gliomas arise following biallelic Nf1 and Tp53 inactivation in NSCs within the lateral ventricle germinal zone, 35 the cells from which Nf1 low-grade gliomas arise has proven more elusive. Using a series of Cre driver lines to conditionally inactivate the Nf1 tumor suppressor gene in several potential progenitor cell types at various times during development, recent studies have revealed that Nf1 mouse optic gliomas most likely arise from neuroglial progenitors within the germinal layer of the third ventricle (TVZ). In these experiments, Nf1þ / À mice in which the Nf1 gene was inactivated in NG2 þ progenitors did not develop brain tumors, excluding this cell type as the cell of origin for optic glioma. 51 Similarly, Nf1þ / À mice in which the Nf1 gene was inactivated in postnatal GFAP þ astrocytes did not form gliomas: 52 Only Nf1þ / À mice in which Nf1 gene inactivation occurred between 11.5 and 16.5 days of embryonic development in GFAP þ neuroglial progenitors developed optic gliomas. 52 As both the lateral and TVZ contain neuroglial progenitors, it is possible that Figure 3 . Regulation of neuroglial cell proliferation. Neurofibromin operates as a tumor suppressor protein by accelerating the conversion of the RAS proto-oncogene from its active, GTP-bound state to its inactive, GDP-bound state. Loss of neurofibromin expression, as seen in NF1-associated gliomas, results in increased RAS-GTP levels and hyperactivation of downstream RAS signaling pathways, to result in increased cell growth. RAS activation following neurofibromin loss leads to high levels of MEK/ERK and PI3K/AKT/mTOR activity. Deregulated BRAF kinase activity leads to increased MEK/ERK signaling to result in high levels of mTOR activation and increased cell growth. The asterisks denote the molecular targets for which clinically-available pharmacological inhibitors exist for the potential treatment of PAs in children.
both germinal zones could provide the cells of origin for Nf1 optic glioma.
Subsequent transcriptomal analyses revealed that NSCs from the TVZ and those from the lateral ventricle SVZ represent two molecularly-distinct stem cell populations. 52 Moreover, the observation that TVZ NSCs, but not their lateral ventricle-SVZ counterparts, exhibit increased proliferation in vitro and increased glial differentiation in vivo following Nf1 gene inactivation demonstrates that murine Nf1 optic gliomas most likely arise from neuroglial progenitors residing within the TVZ. This conclusion is further supported by previous studies of human optic glioma, demonstrating that a discrete population of GFAPpositive radial glial cells extends bilaterally from the floor of the TVZ to the optic nerve. 53 Unlike Nf1 low-grade optic glioma, experimental mouse models for f-BRAF-associated sporadic PA are currently unavailable. Several studies have shown that ectopic expression of either constitutively-activated RAF-1 or BRAF V600E alone is not sufficient to induce gliomas in mice, suggesting that an activated BRAF mutation alone may not be an oncogenic driver. [54] [55] [56] However, RAF-1 and BRAF V600E mutations are rare mutations in PA relative to the signature f-BRAF genetic alteration. 57 Using the most common f-BRAF genetic alteration (KIAA1549 ex16 -BRAF ex9 ), recent studies have revealed similar cell of origin effects. 34 While ectopic f-BRAF expression increases cerebellar mouse NSC proliferation, it has no effect on primary mouse astrocyte growth in vitro. In addition, mice transplanted with f-BRAF-expressing cerebellar NSCs develop low-grade glioma-like lesions within the cerebellum in vivo. While deregulated BRAF activity leads to increased proliferation in mouse NSCs, other studies have indicated that this effect is transient, and is followed by oncogene-induced senescence in human PA-associated glioma stem cells. 58, 59 Collectively, these results underscore the importance of cellular context and developmental age as important determinants of low-grade glioma tumorigenesis.
BRAIN REGION
While malignant gliomas can arise in nearly any location within the central nervous system, glial cell tumors (astrocytomas or gliomas) are most frequently observed in the cerebellum, brainstem and optic pathway/hypothalamus in children. 3 An association between genetic mutation and tumor location is one of the earliest recognized features in low-grade gliomas. Somatic BRAF rearrangement is specific to sporadic PAs and more frequent in cerebellar, but rare in supratentorial hemispheric, PAs. In contrast, NF1-associated PAs are mainly seen in the optic pathway and brainstem, but uncommonly arise in the cerebellum or cortex. 22, 57, 60, 61 Although the molecular bases for these region-specific distributions have not been fully elucidated, one key determinant could be cell-intrinsic responses to specific glioma-associated genetic alterations. Previous studies from PAs and another glial neoplasm (ependymoma) have suggested that glial tumors of the same histological types often comprise clinically and molecularlydistinct subgroups retaining specific signatures that reflect their respective brain regions of origin. 38, 40, 62 In this regard, astrocytes from different brain regions (brainstem, optic nerve, cerebellum and neocortex) harbor unique gene expression signatures. 63 One of the differentially-expressed genes in mouse neocortical astrocytes relative to all other astrocyte populations was the Nf1 tumor suppressor gene. Consistent with significantly lower levels of neurofibromin, loss of Nf1 expression in cortical astrocytes had no effect on cell proliferation in vitro, whereas Nf1 loss in optic nerve, cerebellar and brainstem astrocytes resulted in increased proliferation. 63 Similarly, mouse NSCs from the brainstem exhibit increased proliferation and gliogenesis following Nf1 inactivation, whereas neocortical NSCs did not. 31 Unlike the situation with astrocytes, this differential response to Nf1 loss was not the consequence of reduced neurofibromin expression, but rather resulted from differential expression of the mTOR component rictor. 31 In brainstem NSCs, which express fivefold more rictor relative to cortical NSCs, Nf1 loss results in increased mTORC2-mediated Akt activation and p27 degradation, and leads to enhanced NSC proliferation and glial differentiation.
Similar to NF1, brain region heterogeneity also contributes to the patterning of sporadic f-BRAF-associated PA. While NSCs from the TVZ and cerebellum exhibit increased proliferation following f-BRAF expression, f-BRAF-expressing NSCs from the lateral ventricle-SVZ or neocortex do not. 34, 52 This brain region-specific effect is not related to the ability of f-BRAF to activate MEK/mitogen-activated protein kinase signaling, but rather reflects the ability of f-BRAF to phosphorylate tuberin and activate mTOR in neocortex NSCs. Together, these findings suggest that unique populations of location-specific progenitor cells are the cells of origin for histologically-similar glial cell tumors, and may confer distinct molecular properties on gliomas arising in different brain regions.
LOCAL MICROENVIRONMENT
In order to recapitulate NF1-associated gliomagenesis in mice, it is necessary to inactivate both copies of the Nf1 gene in astroglial progenitor cells. As conventional Nf1 knockout (Nf1À / À ) mice are embryonic lethal, 64, 65 mice in which the Nf1 gene was conditionally inactivated in specific cell populations were generated using Cre-LoxP technology. 66, 67 Surprisingly, conditional knockout mice with complete loss of neurofibromin expression in GFAP þ astroglial progenitor cells did not develop brain tumors, suggesting that other factors are required for tumorigenesis.
As children with NF1 start life with one functional and one nonfunctional NF1 gene in every cell of their bodies (NF1þ / À humans), Nf1þ / À mice were employed to generate Nf1þ / À mice lacking Nf1 expression in astroglial progenitor cells. Using two independent GFAP-Cre driver strains to inactivate the Nf1 gene in neuroglial progenitors during embryogenesis, the majority of Nf1þ / À mice with astroglial Nf1 loss (Nf1þ / À GFAP CKO mice) develop optic gliomas. 68 These unexpected findings suggested that Nf1 optic gliomagenesis requires coupling of complete Nf1 loss in neuroglial progenitors with reduced Nf1 gene expression in non-neoplastic cells. Moreover, it argues that non-neoplastic Nf1þ / À stromal cells are required for Nf1 optic glioma formation.
Previous studies have shown that endothelial cells, reactive astrocytes and microglia (macrophage-like immune system cells) are among the many non-cancerous cells capable of producing growth factors that increase preneoplastic and neoplastic cell growth. 35, 69, 70 Although the other stromal cell types are likely important for creating a permissive microenvironment for glioma formation and continued growth, subsequent studies focused on microglia, based on their abundance in human sporadic and NF1-associated PA. 71, 72 In this respect, microglia comprise 30-50% of the total number of cells in these tumors, and have been implicated in the maintenance of brain homeostasis, including neuronal survival, 73 synaptic function 74, 75 and neurotrophic factor production. 76 In addition, reactive gliosis in response to injury is partially dependent on microglia/macrophage-induced sonic hedgehog activation in astrocytes, 77 raising the possibility that microglia promote both reactive gliosis and endothelial cell proliferation. 78 Consistent with this observation, increased numbers of microglia were found in Nf1þ / À GFAP CKO mouse optic nerves before obvious optic glioma formation. 71 Moreover, Nf1þ / À microglia, but not wild-type microglia, increase the proliferation of Nf1À / À astrocytes in a paracrine fashion in vitro. 79 Additional evidence for a critical role for microglia in optic glioma proliferation derives from pharmacologic and genetic microglia inhibition studies. [79] [80] [81] First, treatment of Nf1þ / À GFAP CKO mice with minocycline to impair microglia function results in reduced optic glioma tumor proliferation. Second, Nf1þ / À microglia (but not Nf1-deficient astrocytes) exhibit increased JNK activation, such that pharmacologic JNK inhibition of microglia in Nf1þ / À GFAP CKO mice attenuates tumor cell proliferation. Third, genetically reducing microglia following gancyclovir-mediated death in Nf1þ / À GFAP CKO mice expressing the thymidine kinase gene in monocytes (CD11b-TK mice) reduces optic glioma tumor proliferation.
To determine whether microglia are required for optic gliomagenesis, recent work has employed mice with impaired fractalkine receptor (CX3CR1) expression.
82 CX3CR1 is expressed in resident brain microglia and partly drives microglia infiltration and function in response to chemokines. 82, 83 Nf1þ / À GFAP CKO mice develop optic glioma by 2-3 months of age, 67, 71 while mice in which one Cx3cr1 allele was silenced (Nf1þ / À GFAP CKO-CX3CR1 mice) have reduced numbers of optic nerve microglia at 6 weeks and 3 months of age and no evidence of glioma. 84 However, by 4 months of age, the numbers of microglia have normalized and optic gliomas are now evident, further underscoring the importance of these stromal cell types in both glioma formation and maintenance.
The notion that neoplastic glial cells release soluble factors (stromagens) that recruit or activate microglia, which in turn produce additional tumor-promoting molecules (gliomagens) to increase the proliferation, survival and invasion of neoplastic cells has recently gained traction (Figure 4) . [85] [86] [87] [88] One of these potential gliomagens is the stroma-derived growth factor CXCL12, a ligand for the CXCR4 and CXCR7 chemokine receptors. 89 First, high levels of CXCL12 are found in young children and mice along the optic pathway, but not in adults. 90 Second, Nf1þ / À microglia produce high levels of CXCL12 relative to their wild-type counterparts. Third, CXCL12 increases the survival of Nf1-deficient astrocytes, but causes apoptosis in wild-type astrocytes. As neurofibromin positively regulates cyclic adenosine monophosphate (cAMP) levels, 91, 92 the lower intracellular cAMP levels in Nf1À / À astrocytes has been shown to enhance cell survival in response to CXCL12. 90 In this regard, defective cAMP generation in Nf1-deficient astroglial cells may influence gliomagenesis. Consistent with this hypothesis, treatment of Nf1þ / À GFAP CKO mice with the phosphodiesterase-4 (PDE4) inhibitor, Rolipram, elevates cAMP levels by blocking cAMP degradation, and attenuates Nf1 mouse optic glioma growth in vivo. 93 Conversely, lentiviral delivery of phosphodiesterase-4 into the forebrains of Nf1þ / À GFAP CKO mice locally lowers cAMP levels, and results in ectopic glioma formation in some mice. 93 These findings argue that CXCL12 is one critical stromal determinant important for dictating NF1-associated gliomagenesis.
Currently, little is known about the role of the tumor microenvironment in sporadic PAs. Although f-BRAF expression is sufficient to induce glioma-like lesions in the cerebellum of mice in vivo, it is possible that f-BRAF expression in the proper cell type (cerebellar NSCs) must be coupled with brain region-specific stromal constraints. For example, in MB, the expression of hepatocyte growth factor in cerebellar neural progenitor cells in the setting of enhanced sonic hedgehog signaling increases the frequency of MB formation. 94 With the recent development of a novel conditional f-BRAF mouse (Kaul A, Chen Y-H and Gutmann DH, manuscript in preparation), the influence of the local microenvironment is now being explored in mechanistic detail.
GENOMIC CONTRIBUTIONS TO GLIOMAGENESIS
Accumulating evidence from a number of studies has demonstrated that epigenetic changes may also influence tumorigenesis. 95, 96 Reilly and colleagues 97 have employed Nf1 GEM strains harboring heterozygous mutations in both the Nf1 and p53 genes (NPcis mice) to elucidate the role of genomic modifiers in gliomagenesis. In these studies, they have shown that gliomas form at a higher frequency on the inbred C57BL/6J (B6) genetic background relative to the 129S4/SvJae (129) background. Subsequent experiments demonstrated that B6 alleles on mouse chromosome 11 were found to confer this dominant susceptibility. 98 Subsequent studies have identified other modifier loci on mouse chromosomes 5 and 12.
99,100 Collectively, these findings establish that the existence of epigenetic or polymorphic differences that modify the susceptibility of mice to gliomagenesis, and raise the intriguing possibility that similar loci exist in children with NF1 that likewise predispose them to glioma development.
CONCLUSIONS
There are a number of clinical challenges to the management of patients with PA. Surgical resection is considered the treatment of choice in children, and usually results in excellent long-term survival rates. 101, 102 Unfortunately, a significant number of these gliomas (for example, NF1-PA) involve the optic pathway or deep midline structures, and are not amenable to complete resection. For these tumors, nonsurgical strategies, including chemotherapy and radiation therapy, are usually implemented. However, radiotherapy is not recommended for the treatment of NF1-associated optic gliomas, as children with NF1 have a propensity to develop secondary central nervous system tumors following radiation, 103 as well as significant long-term neurocognitive and endocrine impairments, which may not be obvious for 5-10 years following the completion of treatment. 101, 104 Over the past decade, there has been an explosion in our understanding of the molecular basis for NF1-related gliomagenesis and the contributions of tumor microenvironment, cell of origin, and genetic modifiers to glioma formation. Although Nf1 inactivation in glial lineage cells is a necessary step in oncogenesis, it must occur in a specific susceptive cell type capable of expanding in response to loss of neurofibromin growth regulation. Moreover, glioma formation in children with NF1 is further restricted by developmental constraints, brain regionspecific determinants, patient age, genomic background and the presence of a supportive local microenvironment ( Figure 5 ). The fact that there exist a number of conditions that must be met in order for gliomagenesis to occur may partly explain why the majority of children with NF1 do not develop brain tumors. In addition, each of these factors not only influences tumorigenesis, but also glioma behavior (vision loss, progression) and perhaps response to therapy. With the availability of an emerging number of potential preclinical GEM glioma models, it now becomes possible to identify and evaluate potential therapeutic strategies that leverage these unique requirements and conditions.
Although less is known about the conditions that dictate f-BRAFassociated glioma formation and growth, it is highly likely that some of the same rules that govern NF1-PA biology are applicable to their sporadic counterparts. The potential for shared lessons is underscored by the finding that mTOR activation is a signature of both sporadic and NF1-associated PA. In this regard, future studies focused on understanding the interplay of all of these molecular and cellular determinants may facilitate the design of more efficient strategies to treat these low-grade brain tumors without negatively impacting on the developing brain. Moreover, it is equally plausible that further elucidation of these constraints and conditions will reveal predictive modifiers of glioma behavior. Recent clinical studies have shown that girls with NF1 younger than 2 years of age harboring gliomas involving the postchiasmatic optic radiations are more likely to behave in a clinically-aggressive manner. 105 Future clinical studies coupled with basic science investigation and genomic analyses may one day yield a series of predictive biomarkers that allow clinicians to stratify children with low-grade gliomas into clinically-relevant groups for surveillance and potential targeted treatment. Figure 5 . Pediatric gliomas are defined by numerous conditions. Pediatric glioma formation requires that cancer-causing genetic mutations occur in specific susceptible preneoplastic cells (glial cells or stem cells) within particular brain regions. The local microenvironment is highly influenced by the specific brain region, as well as genomic factors (patient sex, genomic modifiers). Moreover, the dynamic relationship between preneoplastic/neoplastic neuroglial and non-neoplastic stromal cells is also impacted by the patient age and genomic modifiers. Distinct subgroups of patients with lowgrade glioma could reflect their unique clinicopathological features such as the cell of origin, brain region, stromal factors or genomic modifiers. Each of these subgroups of children may have different clinical outcomes and responses to conventional or targeted therapy.
